Search
Displaying 201–210 of 689 for “retinitis clinical trial”
-
VISIONS 2024, the global conference of the Foundation Fighting Blindness, provides an excellent opportunity to connect with others from the blind and low vision community and learn about the latest research advancements, products and services for members of our community.
-
Eye on the Cure Podcast | Episode 86: Lenore von Krusenstiern, MD, PhD
Eye on the CureDr. Lenore von Krusenstiern talks about Bluerock’s clinical trial for a photoreceptor replacement therapy for people with inherited retinal conditions such as retinitis pigmentosa and cone-rod dystrophy.
-
Eye on the Cure Podcast | Episode 67: Dr. Peter Campochiaro
Eye on the CureDr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in people with retinitis pigmentosa. The powerful antioxidant has moved into a 30+ site, Phase 3 clinical trial called NAC Attack.
-
The Retinal Research Community Mourns the Loss of Retinal Research Pioneer Thierry Léveillard
Beacon StoriesDr. Léveillard helped discover and develop a gene-agnostic, cone-preserving therapy for retinitis pigmentosa that’s moving into a clinical trial.
-
A Surprising Number of Carrier Females are Affected by X-Linked Retinitis Pigmentosa
Research News40 percent of genetically tested XLRP carriers showed a definitive abnormality in at least one of three visions tests.
-
Opus Genetics Acquires Rights to Gene Therapies for BEST1 and RP (RHO)
Research NewsThe company plans to seek clinical trial authorization for the BEST1 gene therapy during the second half of 2023
-
#GivingTuesdayNow Featured Researcher Dr. Shannon Boye
Research NewsA Lifelong Science Nerd is Winning the Fight Against Blindness
-
Foundation Investing in Drug to Slow Many Forms of RP
Research NewsThe Foundation Fighting Blindness Clinical Research Institute (FFB-CRI) has announced an investment of up to $7.5 million to advance the potential therapy into and through a Phase II clinical trial.
-
A Steady Hand in Saving Vision
Research NewsSubretinal injection is the most common form of delivery for gene therapies currently in clinical trials.
-
ARVO 2016: What Does It Take to Develop a Stem-Cell Therapy for the Retina?
Research NewsThere are innumerable considerations for researchers developing therapies.
.png)
